iShares Global Clean Energy ETF vs Twist Bioscience Corp — how do they compare? iShares Global Clean Energy ETF trades at $17.26 (market cap $2.27B), while Twist Bioscience Corp trades at $155.9 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 4.4× iShares Global Clean Energy ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Twist Bioscience Corp for 27 Days on average.
| ICLN | TWST | |
|---|---|---|
Market Cap | $2.27B | $10.08B |
Volume | 6,845,064 | 4,229,037 |
52-Week High | $23.75 | $205.00 |
52-Week Low | $15.78 | $25.45 |
Typical Hold Time | 87 Days | 27 Days |
Sector | — | Health |
Enterprise Value | — | $10.01B |
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.31, down 1.31% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF's financial ratios are unavailable in the provided data, but recent news highlights its focus on global clean energy with 105 holdings and a 0.38% expense ratio. It faces volatility, with a 57.2% maximum drawdown noted in comparisons against traditional energy ETFs.
The outlook for ICLN is mixed; geopolitical tensions and global renewable energy investments provide tailwinds, but high volatility and competition from fossil fuel ETFs pose risks. Investors should weigh its growth potential against expense ratios and performance consistency in the evolving energy sector.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →